Boiron Inc.'s trial victory will stand over class claims that it falsely touted a homeopathic flu product at such retailers as
The jury reasonably believed Boiron’s clinical studies and anecdotal evidence related to the effectiveness of its Oscillococcinum product, the U.S. Court of Appeals for the Ninth Circuit said.
Neither side tested the product, known as Oscillo, to see if it contained any therapeutic ingredient.
As a result, the jury heard a battle of the experts who offered their opinions about the medicine and whether it was ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.